肺癌靶向载体研究进展  

Advances in research on lung cancer targeting carriers

作　　者：曹成明[1] 刘金泳[1] 臧林泉[1] 

机构地区：[1]广东药学院药科学院,广东广州510006

出　　处：《广东药学院学报》2012年第1期94-97,共4页Academic Journal of Guangdong College of Pharmacy

基　　金：国家"重大新药创制"科技重大专项(2011ZX09102-001-31);广东省科技计划项目(2010B031500034);广州市科技计划项目(2010J-E091);中山市科技计划项目(2009H018)

摘　　要：目前肺癌的治疗仍以手术和化疗为主,以细胞毒为主的化学治疗难免会产生较多的严重不良反应,因此,开发一种能增强化疗药物的治疗效果且能降低其毒副作用的肺癌靶向性药物载体,一直是国内外的研究热点。本文对肺癌靶向性载体进行综述。At present,surgery and chemotherapy are still primarily used during lung cancer treatment.The use of cytotoxic agents in chemotherapy causes more serious adverse reactions.Therefore,the exploitation of lung cancer target carrier,which enhance the effect and reduce the toxicity of chemotherapy observably,has been a hot research topic at home and abroad.The lung cancer targeting carriers are reviewed in this article.

关 键 词：肺癌 靶向性 药物载体 研究进展 

分 类 号：R734.2[医药卫生—肿瘤]